Caiqi Liu*, Ci Han†, Jinfeng Liu‡
Oncology Research, Vol.27, No.8, pp. 965-978, 2019, DOI:10.3727/096504019X15498329881440
Abstract Toll-like receptors (TLRs) are associated with tumor growth and immunosuppression, as well as apoptosis and
immune system activation. TLRs can activate apoptosis and innate and adaptive immunity pathways, which
can be pharmacologically targeted for the development of anticancer oncotherapies. Several studies and clinical trials indicate that TLR agonists are promising adjuvants or elements of novel therapies, particularly when
used in conjunction with chemotherapy or radiotherapy. An increasing number of studies suggest that the activation of TLRs in various cancer types is related to oncotherapy; however, before this finding can be applied
to clinical practice, additional studies are required. Research suggests… More >
Login
Register
